ArticleJournal of translational medicine2025
In depth characterisation of the proteome of MIS-C and post COVID-19 infection in children reveals inflammatory pathway activation and evidence of tissue damage.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMultisystem inflammatory syndrome in children (MIS-C) is a rare but severe complication that arises between two and six weeks after initial SARS-CoV-2 infection. The mechanisms underlying why only a subset of children develop this hyperinflammatory response remain unclear.
methodsWe performed an in-depth proteomic analysis of plasma samples from children before and after SARS-CoV-2 infection, including those who developed MIS-C. Proteomic profiling was conducted using high-throughput technologies, and findings were validated using publicly available datasets.
resultsHealthy children showed minimal changes in the circulating proteome following SARS-CoV-2 infection, with no evidence of ongoing inflammation. In contrast, children with MIS-C exhibited significant activation of pro-inflammatory pathways and elevated circulating markers of myocardial and vascular injury.
conclusionsOur data suggest that SARS-CoV-2 infection alone does not cause sustained proteomic alterations in most children. However, MIS-C is associated with a distinct inflammatory and vascular injury signature. Several candidate diagnostic biomarkers for MIS-C were identified and validated in silico, offering promising avenues for future diagnostic and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.